Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
Fabbiani M, Borghetti A, Squillace N, Colafigli M, Taramasso L, Lombardi A, Rossetti B, Ciccullo A, Colella E, Picarelli C, Berruti M, Latini A, Montagnani F, Sambo M, Di Biagio A, Gori A, Di Giambenedetto S, Bandera A. Fabbiani M, et al. Among authors: latini a. J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):119-127. doi: 10.1097/QAI.0000000000002525. J Acquir Immune Defic Syndr. 2021. PMID: 33306566
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection.
Scientific Coordination Committee; Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A; Rapporteur Committee; Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. Scientific Coordination Committee, et al. New Microbiol. 2012 Jul;35(3):259-77. Epub 2012 Jun 30. New Microbiol. 2012. PMID: 22842596 Free article. No abstract available.
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.
Armenia D, Soulie C, Di Carlo D, Fabeni L, Gori C, Forbici F, Svicher V, Bertoli A, Sarmati L, Giuliani M, Latini A, Boumis E, Zaccarelli M, Bellagamba R, Andreoni M, Marcelin AG, Calvez V, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM. Armenia D, et al. Among authors: latini a. PLoS One. 2014 Aug 25;9(8):e105853. doi: 10.1371/journal.pone.0105853. eCollection 2014. PLoS One. 2014. PMID: 25153969 Free PMC article.
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
Zaccarelli M, Fabbiani M, Pinnetti C, Borghi V, Giannetti A, Sterrantino G, Lorenzini P, Latini A, Loiacono L, Colafigli M, Ammassari A, D'Ettorre G, Plazzi M, Di Giambenedetto S, Antinori A. Zaccarelli M, et al. Among authors: latini a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19802. doi: 10.7448/IAS.17.4.19802. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397546 Free PMC article.
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R. Fabbiani M, et al. Among authors: latini a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397552 Free PMC article.
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C, Di Giambenedetto S, Maggiolo F, Lorenzini P, Fabbiani M, Tommasi C, Latini A, Ammassari A, Loiacono L, Sterrantino G, Bellagamba R, Boumis E, Antinori A, Zaccarelli M. Pinnetti C, et al. Among authors: latini a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19812. doi: 10.7448/IAS.17.4.19812. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397556 Free PMC article.
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort.
Pinnetti C, Di Giambenedetto S, Maggiolo F, Fabbiani M, Sterrantino G, Latini A, Lorenzini P, Ammassari A, Loiacono L, Bellagamba R, Boumis E, Cauda R, Antinori A, Zaccarelli M. Pinnetti C, et al. Among authors: latini a. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):e147-50. doi: 10.1097/QAI.0000000000000727. J Acquir Immune Defic Syndr. 2015. PMID: 26090757 No abstract available.
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.
Fabbiani M, Zaccarelli M, Latini A, Sterrantino G, D'Ettorre G, Grima P, Mondi A, Rossetti B, Borchi B, Giuliani M, Antinori A, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: latini a. HIV Med. 2016 May;17(5):385-9. doi: 10.1111/hiv.12313. Epub 2015 Sep 22. HIV Med. 2016. PMID: 26394902 Free article.
Perceptions of Human Papillomavirus (HPV) infection and acceptability of HPV vaccine among men attending a sexual health clinic differ according to sexual orientation.
Giuliani M, Vescio MF, Donà MG, Latini A, Frasca M, Colafigli M, Farinella M, Rezza G, Cristaudo A. Giuliani M, et al. Among authors: latini a. Hum Vaccin Immunother. 2016 Jun 2;12(6):1542-50. doi: 10.1080/21645515.2015.1115935. Epub 2016 Jan 11. Hum Vaccin Immunother. 2016. PMID: 26752151 Free PMC article.
408 results